Vanda Pharmaceuticals (VNDA) Accumulated Expenses (2010 - 2018)

Vanda Pharmaceuticals' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $3.4 million for Q1 2018.

• In Q1 2018, Accumulated Expenses rose 21.03% year-over-year to $3.4 million; the TTM figure through Mar 2018 stood at $3.4 million (up 21.03% YoY), while the FY2017 annual figure was $4.4 million, down 87.12% from the prior year.
• Accumulated Expenses came in at $3.4 million for Q1 2018 at Vanda Pharmaceuticals, down from $4.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $43.6 million in Q2 2015 to a low of $495000.0 in Q4 2014.
• A 5-year average of $12.6 million and a median of $5.8 million in 2016 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 7081.82% in 2015 and sank 87.12% in 2017, its largest moves.
• Vanda Pharmaceuticals' Accumulated Expenses stood at $495000.0 in 2014, then surged by 7081.82% to $35.6 million in 2015, then fell by 4.01% to $34.1 million in 2016, then tumbled by 87.12% to $4.4 million in 2017, then decreased by 21.55% to $3.4 million in 2018.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $3.4 million, $4.4 million, and $3.6 million for Q1 2018, Q4 2017, and Q3 2017 respectively.

Peer Comparison